Eli Lilly Reduces Zepbound Prices in Weight Loss Drug Market Competition
Eli Lilly has announced significant price reductions for its weight loss drug Zepbound, enhancing accessibility for patients and encouraging usage of its digital health platform, LillyDirect. Starting this week, patients can access single-dose vials of Zepbound through the Zepbound Self Pay Journey Program at a monthly cost of $299, down from $349. The 5-milligram dose will now be priced at $399, reduced from $499, while all other approved doses will be available at $449 per month.
Eli Lilly’s Zepbound Pricing Overview
- Single-dose vial price: $299/month (from $349)
- 5-milligram dose: $399/month (from $499)
- All other approved doses: $449/month
The new pricing strategy follows Eli Lilly’s recent announcement regarding the price reduction for Zepbound multi-dose pens, which is still awaiting approval from the Food and Drug Administration (FDA). By April 2026, Medicare patients could pay a maximum of $50 per month for Zepbound if the drug receives FDA approval.
Price Structure for Multi-Dose Pens
- Price for lowest dose multi-dose pen: $299
- Refill cost for multi-dose pen: Up to $449
In addition to Zepbound, Eli Lilly offers orforglipron—a once-a-day weight loss pill. This medication will also be priced competitively, with the lowest dose starting at $149, and higher doses priced up to $399.
Competition and Industry Implications
Eli Lilly’s announcement comes as it competes with Novo Nordisk, which produces weight loss medications like Wegovy and Ozempic. Both companies are developing direct-to-consumer platforms to facilitate patient access and reduce barriers to medication. Novo Nordisk launched its platform, NovoCare Pharmacy, in March to provide affordable options for those without insurance or paying high standard prices.
The ongoing competition in the weight loss drug market is set to benefit patients as both companies strive to expand their reach and enhance affordability.
